Assessment of EGFR and KRAS mutation status from FNAs and core‐needle biopsies of non‐small cell lung cancer

E-ISSN： 1934-6638|123|4|230-236

ISSN： 1934-662x

Source： CANCER CYTOPATHOLOGY, Vol.123, Iss.4, 2015-04, pp. : 230-236

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Can EGFR mutation status be reliably determined in pre‐operative needle biopsies from adenocarcinomas of the lung?

APMIS (ELECTRONIC), Vol. 123, Iss. 4, 2015-04 ,pp. : 289-297

John Wiley & Sons Inc

Access to resources Recommend Favorite

Detection of EGFR T790M Mutation in Pericardial Effusion from a Non-Small Cell Lung Cancer Patient with Erlotinib Therapy

Case Reports in Oncology, Vol. 6, Iss. 1, 2013-01 ,pp. : 15-20

Karger

Access to resources Recommend Favorite

The impact of EGFR mutations on gefitinib sensitivity in non-small cell lung cancer

By Suzuki Takeshi Mitsudomi Tetsuya Hida Toyoaki

Personalized Medicine, Vol. 1, Iss. 1, 2004-12 ,pp. : 27-34

Future Medicine

Access to resources Recommend Favorite

The Role of EGFR-TK Inhibition in Non-Small Cell Lung Cancer

Oncology Research and Treatment, Vol. 28, Iss. 12, 2005-12 ,pp. : 619-620

Karger

Access to resources Recommend Favorite

Selumetinib in Advanced Non Small Cell Lung Cancer (NSCLC) Harbouring KRAS Mutation: Endless Clinical Challenge to KRAS-mutant NSCLC.

Reviews on Recent Clinical Trials, Vol. 8, Iss. 2, 2013-06 ,pp. : 93-100

Bentham Science Publishers

Access to resources Recommend Favorite